Monitoring MRD in Patients with AML

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the US.

C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant studies and emerging therapeutic approaches.